Next Science (ASX:NXS) - Outgoing CEO and Managing Director, Judith Mitchell
Outgoing CEO and Managing Director, Judith Mitchell
Source: Next Science
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Biotech company Next Science (NXS) has received CE Mark approval for its BlastX product
  • This approval allows Next Science to apply and sell BlastX in each market in the European Union and the United Kingdom
  • BlastX is an antimicrobial wound gel that deconstructs the bacterial biofilm and eliminates the bacteria in wounds to maintain a moist wound environment favourable for healing
  • It is used for the treatment of non-healing wounds such as venous leg ulcers, diabetic foot ulcers, and bed sores
  • Next Science has ended the day 9.7 per cent in the green with shares trading at $1.30

Next Science (NXS) has received CE Mark approval for its BlastX product.

This approval allows Next Science to apply and sell BlastX in each market in the European Union and the United Kingdom.

Additionally, this approval is the second for the company, having received CE Mark approval for its Bactisure Surgical Lavage Product in March.

BlastX is an antimicrobial wound gel that deconstructs the bacterial biofilm and eliminates the bacteria in wounds to maintain a moist wound environment favourable for healing.

It is used for the treatment of non-healing wounds such as venous leg ulcers, diabetic foot ulcers, and bed sores. It also prevents infections in acute wounds and surgical wounds.

Wounds such as these are difficult to treat, cause a decline in quality of life, and increase mortality, pain, and suffering.

A study completed in Texas showed that combining BlastX with custom antibiotics increased chronic wound closures by 40 per cent in a four-week randomised controlled trial.

“The receipt of a CE Mark approval for BlastX represents the successful conclusion of three years of work and marks a major milestone for Next Science as we pursue our mission to heal patients and save lives worldwide by reducing the impacts of biofilms on human health,” Managing Director Judith Mitchell said.

“The CE Mark is a minimum requirement for many other jurisdictions so we can now work on further approvals,” she added.

Next Science has ended the day 9.7 per cent in the green, with shares trading at $1.30 in a $230.1 million market cap.

NXS by the numbers
More From The Market Online

Recce breathes better on positive lung infection drug pilot test results

Recce Pharmaceuticals Ltd has revealed positive results from its pilot test on synthetic drug Recce 327,…
The Market Online Video

Breaking barriers in cancer treatment: Race Oncology pioneers a new era with bisantrene

Race Oncology (ASX:RAC) has announced positive results in killing cancer cells in combination with the drug…

Botanix isn’t sweating on FDA approval for Sofdra

Botanix has submitted the last label materials to the FDA seeking approval for Sofdra™ a prescription…

Singular Health launches upgraded DICOM viewer, with patient-friendly features for engagement with medical records

Singular Health Ltd has launched an upgraded version of its DICOM viewer, set to allow greater…